Please use this identifier to cite or link to this item:
|Title:||A phase 1 dose-escalation study: Safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload|
|Authors:||Hugh Young Rienhoff|
Janet L. Kwiatkowski
John B. Porter
Ellis J. Neufeld
FerroKin BioSciences, Inc.
Institute of Medical and Veterinary Science Australia
UCSF Benioff Children's Hospital Oakland
Children's Hospital Boston
The Children's Hospital of Philadelphia
|Citation:||Haematologica. Vol.96, No.4 (2011), 521-525|
|Abstract:||Background: There is still a clinical need for a well-tolerated and safe iron chelator for the treatment of trans-fusional iron overload. We describe the pharmacokinetic properties and safety data after 7 days of dosing of FBS0701, a novel oral, once-daily iron chelator. Design and Methods: This phase 1b dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload, was conducted in 16 adult patients with iron overloaded consequent to transfusions. FBS0701 was given daily for 7 days at doses up to 32 mg/kg and was well tolerated at all dose levels. Results: Pharmacokinetics showed dose-proportionality. The maxium plasma concentration (Cmax) was reached within 60-90 minutes of dosing and the drug was rapidly distributed at the predicted therapeutic doses. The plasma elimination half-life (t1/2) was approximately 19 hours. There were no serious adverse events associated with the drug. Conclusions: On the basis of these safety and pharmacokinetic data, FBS0701 warrants further clinical evaluation in patients with transfusional iron overload. © 2011 Ferrata Storti Foundation.|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.